AstraZeneca makes a quick response to FDA over Brilinta
This article was originally published in Scrip
AstraZeneca has made a speedy response to the US FDA's complete response letter for its novel antiplatelet agent ticagrelor (Brilinta), but questions remain over whether the new analyses submitted will be enough to convince the US agency to approve the product.
You may also be interested in...
Novartis’s AveXis unit has received a CHMP nod for the spinal muscular atrophy gene therapy at its latest meeting, sending it on the final steps to market in the EU.
The arrival of SARS-CoV-2 has focused attention on a potential new way of making vaccines – one that promises to be quicker and cheaper than traditional methods and more reactive to novel virus outbreaks, but also one that remains to be validated.
The German biotech firm has denied receiving any offer from the Trump administration in a wide-ranging conference call that also addressed recent changes at the top, its clinical timeline for a coronavirus vaccine and new funds from the European Commission to boost production.